COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00108810
Recruitment Status : Completed
First Posted : April 19, 2005
Last Update Posted : June 5, 2012
Information provided by (Responsible Party):
ZARS Pharma Inc.

Brief Summary:
The purpose of the study is to evaluate the safety and effectiveness of the investigational ketoprofen patch with a controlled heating patch, compared to placebo (inactive substance) for the treatment of pain caused by osteoarthritis.

Condition or disease Intervention/treatment Phase
Pain Osteoarthritis, Knee Drug: Transdermal Ketoprofen Patch with CHADD Drug: Placebo transdermal patch Phase 2

Detailed Description:
Proof-of-concept study, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of a transdermal ketoprofen patch with CHADD heat versus a placebo patch with dummy heat in patients with mild to moderate pain associated with osteoarthritis of the knee. After screening, patients discontinue all analgesic medication (except ≤325 mg aspirin daily for cardioprotective purposes). Patients selected a target knee (right or left), and all efficacy evaluations were completed with respect to this target knee. After discontinuing analgesics for at least 48 hours, and when the average pain intensity over the previous 24 hours for the target knee was ≥40 mm using a 100 mm visual analog scale (VAS), patients were randomized in a 1:1 fashion to receive treatment with either the transdermal ketoprofen patch with CHADD heat or the placebo patch with dummy heat. Patients treated the target knee each night for 12 hours (± 1 hour) for 4 weeks. Patients returned to the study site every 7 days (± 1 day) for study evaluations. Throughout the study, patients were allowed to take up to 2000 mg acetaminophen per day as rescue medication; however, rescue medication was not allowed within the 48 hours prior to efficacy evaluations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Parallel, Placebo Controlled 4 Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of Transdermal Ketoprofen When Administered With Controlled Heat in Patients With Mild to Moderate OA Pain of the Knee
Study Start Date : April 2005
Actual Primary Completion Date : October 2005
Actual Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Ketoprofen

Arm Intervention/treatment
Experimental: Transdermal Ketoprofen Patch with CHADD Drug: Transdermal Ketoprofen Patch with CHADD
12 hours patch application for 28 days
Other Name: Matrix Transdermal Ketoprofen/CHADD Sytem

Placebo Comparator: Placebo patch and a dummy heating unit Drug: Placebo transdermal patch
12 hours application for 28 days
Other Name: Placebo patch with dummy heating unit

Primary Outcome Measures :
  1. Change from baseline in the WOMAC pain subscale score [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Number of participants wih adverse events [ Time Frame: 28 days ]
  2. Patient Global Satisfaction score [ Time Frame: 28 days ]
    Patient global satisfaction score at Study Visit 5

  3. Mean change from baseline for average pain over the last 24 hours VAS scores [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is between forty (40) and seventy-five (75) years of age.
  • Patient has clinically diagnosed radiographic evidence of osteoarthritis of the knee within the past year.

Exclusion Criteria:

  • Patient has known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) (including aspirin) or has a suspected hypersensitivity, allergy or other contraindication to any compound present in the study medication.
  • Patient has a history of significant gastrointestinal disease or previous gastrointestinal upset following NSAID administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00108810

Layout table for location information
United States, California
SouthBay Pharma Research
Buena Park, California, United States, 90620
United States, District of Columbia
The Center for Rheumatology and Bone Research
Washington, District of Columbia, United States, 20006
United States, Florida
Radiant Research
Daytona Beach, Florida, United States, 32114
University Clinical Research
Pembroke Pines, Florida, United States, 33024
United States, New York
Hospital for Special Surgery
New York City, New York, United States, 10021
Sponsors and Collaborators
ZARS Pharma Inc.
Layout table for investigator information
Principal Investigator: David Borenstein, MD The Center for Rheumatology
Principal Investigator: H F Farmer, MD Radiant Research Inc.
Principal Investigator: Larry Gilderman, DO University Clinical Research
Principal Investigator: Soledad Lee, MD Southbay Pharma Research
Principal Investigator: Joseph A Markenson, MD Hospital for Special Surgery, New York
Layout table for additonal information
Responsible Party: ZARS Pharma Inc. Identifier: NCT00108810    
Other Study ID Numbers: ZMK-202
First Posted: April 19, 2005    Key Record Dates
Last Update Posted: June 5, 2012
Last Verified: May 2012
Keywords provided by ZARS Pharma Inc.:
Mild to Moderate Osteoarthritis (OA) Pain of the Knee
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action